Patents by Inventor Lawrence Lum

Lawrence Lum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Disubstituted and trisubstituted 1,2,3-triazoles as Wnt inhibitors
    Patent number: 10793544
    Abstract: The present disclosure provides compounds that may be useful for inhibiting Wnt pathway comprising compounds of the formula: (Ia) or (Ib) wherein the variables are as defined herein. In some aspects, the compounds may be used to inhibit the Wnt pathway and used to treat cancer, myocardial infarction, osteopetrosis, or used in the maturation of a precursor cell to a mature cell. Also provided herein in are pharmaceutical compositions of the compounds described herein.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: October 6, 2020
    Inventors: Nageswari Yarravarapu, Chuo Chen, Lawrence Lum, Lin You, Chengwei Zhang, Xiaolei Wang, Lishu Zhang
  • Indolinyl-sulfonamide inhibitors of tankyrase and methods of use thereof
    Patent number: 10420758
    Abstract: The present disclosure provides compounds that may be useful for inhibiting the Tankyrase enzyme. In some aspects, these compounds are useful in the treatment of a disease or disorder related to the misregulation of Tankyrase enzyme such as cancer, degenerative diseases, or fibrotic diseases. Also provided herein are compounds may also be used to prevent the elongation of the telomere in a cell.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: September 24, 2019
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Lawrence Lum, Chuo Chen, Xuewu Zhang, Ozlem Kulak, Xiaofeng Wu
  • DISUBSTITUTED AND TRISUBSTITUTED 1,2,3-TRIAZOLES AS WNT INHIBITORS
    Publication number: 20190202804
    Abstract: The present disclosure provides compounds that may be useful for inhibiting Wnt pathway comprising compounds of the formula: (Ia) or (Ib) wherein the variables are as defined herein. In some aspects, the compounds may be used to inhibit the Wnt pathway and used to treat cancer, myocardial infarction, osteopetrosis, or used in the maturation of a precursor cell to a mature cell. Also provided herein in are pharmaceutical compositions of the compounds described herein.
    Type: Application
    Filed: August 31, 2017
    Publication date: July 4, 2019
    Inventors: Nageswari YARRAVARAPU, Chuo CHEN, Lawrence LUM, Lin YOU, Chengwei ZHANG, Xiaolei WANG, Lishu ZHANG
  • GENE DELETION AND RESCUE BY CRISPR-MEDIATED ELIMINATION OF EXON SPLICING ENHANCERS
    Publication number: 20180353622
    Abstract: Disclosed herein are methods for gene inactivation or rescue by cutting genomic DNA at regions of putative exon splicing enhancers with CRISPR-type enzymes.
    Type: Application
    Filed: June 8, 2018
    Publication date: December 13, 2018
    Inventors: Lawrence LUM, Rubina TULADHAR, Tae Hyun HWANG, Yunku YEU, John Tyler PIAZZA, Quinn BARRETT
  • INDOLINYL-SULFONAMIDE INHIBITORS OF TANKYRASE AND METHODS OF USE THEREOF
    Publication number: 20180271848
    Abstract: The present disclosure provides compounds that may be useful for inhibiting the Tankyrase enzyme. In some aspects, these compounds are useful in the treatment of a disease or disorder related to the misregulation of Tankyrase enzyme such as cancer, degenerative diseases, or fibrotic diseases. Also provided herein are compounds may also be used to prevent the elongation of the telomere in a cell.
    Type: Application
    Filed: May 2, 2016
    Publication date: September 27, 2018
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Lawrence LUM, Chuo CHEN, Xuewu ZHANG, Ozlem KULAK, Xiaofeng WU
  • Highly potent inhibitors of porcupine
    Patent number: 9783550
    Abstract: The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: October 10, 2017
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Lawrence Lum, Chuo Chen
  • HIGHLY POTENT INHIBITORS OF PORCUPINE
    Publication number: 20160115177
    Abstract: The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.
    Type: Application
    Filed: May 14, 2014
    Publication date: April 28, 2016
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Lawrence LUM, Chuo CHEN
  • WNT PROTEIN SIGNALLING INHIBITORS
    Publication number: 20150374696
    Abstract: The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.
    Type: Application
    Filed: June 2, 2015
    Publication date: December 31, 2015
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Lawrence LUM, Michael G. ROTH, Baozhi CHEN, Chuo CHEN, Michael E. DODGE, Wei TANG
  • WNT PROTEIN SIGNALLING INHIBITORS
    Publication number: 20150157633
    Abstract: The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.
    Type: Application
    Filed: May 6, 2013
    Publication date: June 11, 2015
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Lawrence Lum, Michael Roth, Baozhi Chen, Michael Dodge, Chuo Chen
  • WNT protein signalling inhibitors
    Patent number: 9045416
    Abstract: The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: June 2, 2015
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Lawrence Lum, Michael G. Roth, Baozhi Chen, Chuo Chen, Michael E. Dodge, Wei Tang
  • Polyclonal bispecific antibody compositions and method of use
    Patent number: 8999398
    Abstract: The invention relates to compositions and methods for treating a host infected with a pathogen. The composition comprising a population of polyclonal bispecific binding molecules that can target and eliminate a host cell infected with the pathogen. Methods for activating and arming cytotoxic immune cells with the composition for use in treating a patient infected with a pathogen are also provided.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: April 7, 2015
    Assignees: TransTarget Inc., Wayne State University
    Inventors: Lawrence Lum, Manley Huang
  • WNT PROTEIN SIGNALLING INHIBITORS
    Publication number: 20140038922
    Abstract: The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.
    Type: Application
    Filed: May 1, 2013
    Publication date: February 6, 2014
    Inventors: Lawrence LUM, Michael G. ROTH, Baozhi CHEN, Chuo CHEN, Michael E. DODGE, Wei TANG
  • Multiplexed luciferase reporter assay systems
    Patent number: 8569002
    Abstract: Inhibitors of luciferase enzymes are disclosed and find use in multiplexed assays using multiple luciferases and multiple inhibitors, in both in vitro and in vivo embodiments.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: October 29, 2013
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Lawrence Lum, Ozlem Kulak
  • Wnt protein signalling inhibitors
    Patent number: 8445491
    Abstract: The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: May 21, 2013
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Lawrence Lum, Michael G. Roth, Baozhi Chen, Chuo Chen, Michael E. Dodge, Wei Tang
  • POLYCLONAL BISPECIFIC ANTIBODY COMPOSITIONS AND METHOD OF USE
    Publication number: 20120269813
    Abstract: The invention relates to compositions and methods for treating a host infected with a pathogen. The composition comprising a population of polyclonal bispecific binding molecules that can target and eliminate a host cell infected with the pathogen. Methods for activating and arming cytotoxic immune cells with the composition for use in treating a patient infected with a pathogen are also provided.
    Type: Application
    Filed: November 5, 2010
    Publication date: October 25, 2012
    Applicants: Wayne State University, Trans Target Inc.
    Inventors: Lawrence Lum, Manley Huang
  • Control panel
    Patent number: D713802
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: September 23, 2014
    Assignee: RGB Systems, Inc.
    Inventors: Osbaldo Rodriguez, Lawrence Lum, Robert M Chaloupecky, Jaysun Stockdell-Giesler, Kate Gentle
  • Control panel
    Patent number: D716740
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: November 4, 2014
    Assignee: RGB Systems, Inc.
    Inventors: Osbaldo Rodriguez, Lawrence Lum, Robert M Chaloupecky, Jaysun Stockdell-Giesler, Kate Gentle, Matthew Soper
  • Control panel
    Patent number: D717249
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: November 11, 2014
    Assignee: RGB Systems, Inc.
    Inventors: Osbaldo Rodriguez, Lawrence Lum, Robert M Chaloupecky, Jaysun Stockdell-Giesler, Kate Gentle
  • Control panel
    Patent number: D721044
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: January 13, 2015
    Assignee: RGB Systems, Inc.
    Inventors: Osbaldo Rodriguez, Lawrence Lum, Robert M Chaloupecky, Jaysun Stockdell-Giesler, Kate Gentle
  • Control panel
    Patent number: D721659
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: January 27, 2015
    Assignee: RGB Systems, Inc.
    Inventors: Osbaldo Rodriguez, Lawrence Lum, Robert M Chaloupecky, Jaysun Stockdell-Giesler, Kate Gentle